Circulating Neprilysin Level Predicts the Risk of Cardiovascular Events in Hemodialysis Patients

Background: Neprilysin inhibition has demonstrated impressive benefits in heart failure treatment, and is the current focus of interest in cardiovascular (CV) and kidney diseases. However, the role of circulating neprilysin as a biomarker for CV events is unclear in hemodialysis (HD) patients. Metho...

Descripción completa

Detalles Bibliográficos
Autores principales: Hwang, Hyeon Seok, Kim, Jin Sug, Kim, Yang Gyun, Lee, Yu Ho, Lee, Dong-Young, Ahn, Shin Young, Moon, Ju-Young, Lee, Sang-Ho, Ko, Gang-Jee, Jeong, Kyung Hwan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Cardiovascular Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8239158/
https://www.ncbi.nlm.nih.gov/pubmed/34212014
http://dx.doi.org/10.3389/fcvm.2021.684297

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8239158/
https://www.ncbi.nlm.nih.gov/pubmed/34212014
http://dx.doi.org/10.3389/fcvm.2021.684297

Ejemplares similares